Skip to content
Screener

Glaukos GKOS Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$79.75M-21.4%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Schering-Plough logo
Schering-PloughSGP
$238.9M+312%
Bausch + Lomb logo
Bausch + LombBLCO
$378M+39.0%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M—
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio5×-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents$114,485$90,813
Short-term investments171,741187,947
Accounts receivable, net138,900108,608
Inventory59,30663,564
Prepaid expenses and other current assets31,34624,052

Item 1. Financial Statements

FAQ

What is Glaukos's cash & equivalents?
Glaukos (GKOS) reported cash & equivalents of $114.49M in Q2 2026.
How has Glaukos's cash & equivalents changed year-over-year?
Glaukos's cash & equivalents increased by 13.6% year-over-year, from $100.81M to $114.49M.
What is the long-term trend for Glaukos's cash & equivalents?
Over 5 years (2020 to 2025), Glaukos's cash & equivalents has grown at a -1.2% compound annual growth rate (CAGR), from $96.6M to $90.81M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Glaukos's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude